BIO

Elizabeth Goacher is a Physician Assistant with Duke University Medical Center, Department of Medicine, Gastroenterology Division, Duke Liver Center, April 2001 to the present. Her pronouns are she/her. She is currently engaged in full time clinical practice in Hepatology. Her clinical work encompasses the full spectrum of liver disease patient population, from early stage disease to end of life, with a particular interest in portal hypertension. She served as Team Lead for the Duke Division of Gastroenterology Advanced Practice group of 25 Advanced Practice Providers 2014-2023. She is also lecturer and preceptor at Duke University School of Medicine Physician Assistant Program. Elizabeth graduated from the Duke University School of Medicine Physician Assistant Program in 1998 after earning her Bachelor of Arts from University of North Carolina at Chapel Hill in 1991. She is past Chair of the Hepatology Associates Committee of the American Association for the Study of Liver Diseases and was a member of the inaugural class of Associate Fellows of AASLD in 2020. When she is not at work, she maintains a health boundary from technology (aka EPIC) and spends as much time outdoors as possible. When asked to design and implement her dream job, she would own and operate a cocktail and tapas venue while instructing fitness classes on a large piece of lakeside property in North Carolina alongside her canine rescue, foster and retraining agency.

MASLD-MASH Content Featuring Elizabeth

Related Content

Serological Workup: A Step-by-Step Guide

July 2025

In this comprehensive video, Sherona Bau, NP from UCLA, breaks down the essential hepatology workup for patients with MASLD (formerly NAFLD) and MASH, offering guidance for both primary care providers and GI/hepatology specialists. Drawing from her extensive clinical experience, she outlines a systematic approach to evaluating abnormal liver ultrasound findings—starting with critical labs to rule out chronic liver conditions like hepatitis B, hepatitis C, autoimmune hepatitis, PBC, and hereditary hemochromatosis. Sherona discusses the importance of ordering ANA, AMA, ferritin, serologies, and even specialized labs like the phosphatidylethanol (PEth) test to uncover alcohol-related liver disease that may be overlooked. She emphasizes the need to screen for cardiometabolic risk factors including type 2 diabetes and dyslipidemia and highlights non-invasive tests such as FibroScan and FIB-4 to help identify patients at risk of advanced fibrosis who may benefit from specialist referral. Most importantly, Sherona addresses the fears many patients face around liver disease progression and life expectancy, encouraging early intervention and coordinated care to improve long-term outcomes. This video is a must-watch for any clinician managing steatotic liver disease.

Watch Now arrow

MASH/MASLD in Type 2 Diabetes: Concurrent Medication Management

July 2025

In this informative episode, Whitney Steinmetz, NP from Presbyterian Medical Group in Albuquerque, NM, explores how to optimize medication strategies for patients with type 2 diabetes who are also living with MASLD and MASH. She discusses why individuals with type 2 diabetes are at significantly higher risk for developing advanced liver fibrosis—highlighting the overlapping metabolic, inflammatory, and insulin-resistant pathways that accelerate liver damage. Whitney breaks down how commonly prescribed diabetes medications—like GLP-1 receptor agonists, SGLT2 inhibitors, TZDs, and dual/triple incretins—impact liver fat, inflammation, and fibrosis progression. She offers practical guidance on selecting therapies that balance glycemic control with hepatic benefits while minimizing polypharmacy. Learn which medications may offer dual cardiometabolic and hepatic advantages, and which should be avoided or used with caution in patients with cirrhosis or advanced fibrosis. Tune in for real-world insights into how advanced practice providers can take ownership of MASH management in diabetes care.

Watch Now arrow